Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Condensation of the lower part of the iliac bone.

Joint bone spine·2026
Same author

Artificial Intelligence in Rheumatology: From Algorithms to Clinical Impact in Osteoporosis and Chronic Inflammatory Rheumatic Diseases.

Journal of clinical medicine·2026
Same author

Impaired organic and mineral extracellular matrix composition in early-onset osteoporosis.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2025
Same author

Evaluation of the efficacy and tolerance of pamidronate in complex regional pain syndrom type 1.

Scientific reports·2025
Same author

Immediate risk factors for fracture recurrence after initial fractures, based on fracture liaison service dataset, and comparison with fall risk factors reported in the literature.

European geriatric medicine·2025
Same author

Causes of Mortality in Intensive Care Units for Patients with Chronic Inflammatory Diseases from the French National Health Data System.

Journal of clinical medicine·2025
Same journal

Evidence-Based Clinical Recommendations for the Appropriate Use of Diagnostic Tests in Pediatric Allergology: Focus on Asthma, Rhinoconjunctivitis, and Keratoconjunctivitis Vernal.

Journal of clinical medicine·2026
Same journal

Surgical and Transcatheter Approach of a Failed Mitral Valve Repair: A Comprehensive Review on Selecting the Most Suitable Approach.

Journal of clinical medicine·2026
Same journal

Hybrid Metaheuristic Feature Selection for Breast Cancer Detection in Digital Mammography: A Feasibility Study with Nested Validation, Benchmarking, and External Stress Testing.

Journal of clinical medicine·2026
Same journal

Identity Transformation and the Role of Accountability in Recovery from Problematic Pornography Use: A Phenomenological-Hermeneutical Study.

Journal of clinical medicine·2026
Same journal

Does Early Surgical Treatment in Degenerative Cervical Myelopathy Have a Favorable Clinical Outcome and Impact on Quality of Life?

Journal of clinical medicine·2026
Same journal

Shear Wave Elastography in Musculoskeletal Imaging: A Narrative Review.

Journal of clinical medicine·2026
See all related articles

Related Experiment Videos

Relevance of Systematic Pre-Biologic Infectious Screening in Chronic Inflammatory Rheumatic Diseases: A Retrospective

Marie Doussiere1,2, Clémence Jouret1, Lara Awad1

  • 1Department of Rheumatology, University Hospital of Amiens, 80000 Amiens, France.

Journal of Clinical Medicine
|June 26, 2026
PubMed
Summary
This summary is machine-generated.

Systematic infectious screening before biologic therapy in rheumatic diseases rarely found active viral infections. Tuberculosis screening, however, frequently altered treatment plans, delaying biologic initiation.

Keywords:
biologic therapychronic inflammatory rheumatic diseaseshepatitis B viruslatent tuberculosispre-treatment infectious screening

Related Experiment Videos

Area of Science:

  • Rheumatology
  • Infectious Diseases
  • Public Health

Background:

  • Routine infectious screening is advised before initiating biologic therapies for chronic inflammatory rheumatic diseases (CIRDs).
  • The clinical utility of this screening in low-prevalence areas needs further investigation.
  • This study assesses screening outcomes and their effect on treatment decisions.

Purpose of the Study:

  • To determine the frequency of abnormal findings during pre-biologic infectious screening in CIRD patients.
  • To evaluate the impact of these findings on the initiation of biologic therapies.
  • To characterize the role of different screening tests in treatment management.

Main Methods:

  • Retrospective single-center study of 418 adult CIRD patients undergoing pre-biologic screening (HIV, HBV, HCV, IGRA, chest X-ray).
  • Screening occurred between January 2019 and June 2025.
  • Primary outcome: proportion of abnormal results and their influence on biologic therapy initiation.

Main Results:

  • No active HIV, hepatitis B virus (HBV), or hepatitis C virus (HCV) infections were detected.
  • Past HBV (2.6%) and HCV (0.7%) infection markers were found, but without detectable viremia, not impacting therapy.
  • Interferon-gamma release assay (IGRA) positivity (4.3%) and indeterminate results (3.1%) were observed, often leading to delayed biologic initiation due to preventive tuberculosis treatment.

Conclusions:

  • Pre-biologic screening identified minimal clinically significant viral infections in this cohort.
  • Screening for latent tuberculosis via IGRA was the primary driver for modifying treatment plans and delaying biologic therapy.
  • Further research is needed for optimized, cost-effective screening strategies, emphasizing tuberculosis risk assessment.